Mineralys Therapeutics, Inc. (NASDAQ:MLYS – Get Free Report) CEO Jon Congleton bought 2,250 shares of the company’s stock in a transaction dated Wednesday, September 6th. The stock was purchased at an average cost of $12.08 per share, for a total transaction of $27,180.00. Following the completion of the acquisition, the chief executive officer now owns 1,044,818 shares in the company, valued at approximately $12,621,401.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Jon Congleton also recently made the following trade(s):
- On Thursday, August 17th, Jon Congleton bought 2,250 shares of Mineralys Therapeutics stock. The stock was purchased at an average cost of $12.10 per share, for a total transaction of $27,225.00.
- On Friday, August 11th, Jon Congleton bought 2,000 shares of Mineralys Therapeutics stock. The stock was purchased at an average cost of $12.89 per share, for a total transaction of $25,780.00.
Mineralys Therapeutics Trading Up 1.1 %
MLYS stock opened at $11.85 on Monday. The business’s fifty day moving average price is $13.77 and its two-hundred day moving average price is $14.81. Mineralys Therapeutics, Inc. has a fifty-two week low of $11.30 and a fifty-two week high of $21.98.
Institutional Inflows and Outflows
Several hedge funds have recently made changes to their positions in the business. Samsara BioCapital LLC bought a new position in shares of Mineralys Therapeutics during the first quarter worth approximately $70,773,000. SR One Capital Management LP bought a new position in shares of Mineralys Therapeutics in the first quarter worth $28,103,000. RTW Investments LP bought a new position in shares of Mineralys Therapeutics in the first quarter worth $14,440,000. BlackRock Inc. increased its position in shares of Mineralys Therapeutics by 18.0% in the second quarter. BlackRock Inc. now owns 884,260 shares of the company’s stock worth $15,077,000 after purchasing an additional 134,571 shares during the period. Finally, Great Point Partners LLC bought a new position in shares of Mineralys Therapeutics in the first quarter worth $9,714,000. 61.66% of the stock is owned by institutional investors.
Analysts Set New Price Targets
Separately, Credit Suisse Group dropped their target price on shares of Mineralys Therapeutics from $38.00 to $37.00 and set an “outperform” rating on the stock in a report on Tuesday, August 8th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Mineralys Therapeutics currently has a consensus rating of “Buy” and an average target price of $36.00.
About Mineralys Therapeutics
Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension.
- Five stocks we like better than Mineralys Therapeutics
- How to Invest in Music Stocks
- MarketBeat Week in Review – 9/4 – 9/8
- How to Invest in Small Cap Stocks
- The Best 5 Small Cap AI Companies to Buy Now
- How to Effectively Use the MarketBeat Ratings Screener
- Miso Robotics Stock: Is an IPO Coming Soon?
Receive News & Ratings for Mineralys Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mineralys Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.